MX2023006817A - Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. - Google Patents
Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.Info
- Publication number
- MX2023006817A MX2023006817A MX2023006817A MX2023006817A MX2023006817A MX 2023006817 A MX2023006817 A MX 2023006817A MX 2023006817 A MX2023006817 A MX 2023006817A MX 2023006817 A MX2023006817 A MX 2023006817A MX 2023006817 A MX2023006817 A MX 2023006817A
- Authority
- MX
- Mexico
- Prior art keywords
- effector cell
- compositions
- cell antigens
- methods related
- antibodies targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123329P | 2020-12-09 | 2020-12-09 | |
| US202163187699P | 2021-05-12 | 2021-05-12 | |
| PCT/US2021/062249 WO2022125576A1 (en) | 2020-12-09 | 2021-12-07 | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006817A true MX2023006817A (es) | 2023-08-14 |
Family
ID=81849994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006817A MX2023006817A (es) | 2020-12-09 | 2021-12-07 | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11555078B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259193A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7850721B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230135575A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021396172A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201588A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006817A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202617780A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022125576A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN116981682A (zh) * | 2020-12-08 | 2023-10-31 | 佳努克斯治疗公司 | 用于抗-cd3结合结构域的肽组合物和方法 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| JP7855148B2 (ja) | 2023-02-10 | 2026-05-07 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法 |
| CN121843965A (zh) * | 2023-07-14 | 2026-04-10 | 佳努克斯治疗公司 | 靶向psma和效应细胞抗原的肿瘤激活抗体相关的组合物和方法 |
| TW202528349A (zh) * | 2023-11-03 | 2025-07-16 | 美商詹努克斯治療有限公司 | 用於靶向psma及cd28之抗體及其用途 |
| WO2026096559A1 (en) * | 2024-11-01 | 2026-05-07 | Janux Therapeutics, Inc. | Antibodies for targeting psma and uses thereof |
| US20260226165A1 (en) * | 2024-12-17 | 2026-08-06 | Merck Sharp & Dohme Llc | Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens |
| WO2026156021A1 (en) | 2025-01-16 | 2026-07-23 | Merck Sharp & Dohme Llc | Bispecific antibody constructs that bind alpp/alppl2 and cd3 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US20010031264A1 (en) | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| JP2009540015A (ja) | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗egfr抗体の凍結乾燥製剤 |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
| KR101652125B1 (ko) | 2007-09-26 | 2016-08-29 | 우드라이 파마 게엠베하 | 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질 |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| MX2011003502A (es) | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| JP6407726B2 (ja) | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 長寿命ポリペプチド結合分子 |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| BR112015000798A2 (pt) * | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| SMT201800335T1 (it) | 2012-11-06 | 2018-09-13 | Bayer Pharma AG | Formulazione di attivatori bispecifici per linfociti t (bite) |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US20160017058A1 (en) | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| UY35484A (es) | 2013-03-15 | 2014-10-31 | Amgen Res Munich Gmbh | Molécula de unión de cadena simple que comprenden ABP de extremo N |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| EP3197916A2 (en) | 2014-09-25 | 2017-08-02 | Amgen Inc. | Protease-activatable bispecific proteins |
| WO2016077505A2 (en) | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| WO2017008844A1 (en) | 2015-07-14 | 2017-01-19 | Biontech Ag | Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR107582A1 (es) | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| AU2017229687A1 (en) | 2016-03-08 | 2018-09-20 | Takeda Pharmaceutical Company Limited | Inducible binding proteins and methods of use |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化t細胞二重特異性分子 |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| HRP20251020T1 (hr) | 2016-05-20 | 2025-10-24 | Harpoon Therapeutics, Inc. | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| CN110072890B (zh) | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| JP2020518240A (ja) | 2017-01-17 | 2020-06-25 | ザ テキサス エー アンド エム ユニバーシティー システム | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| US10730954B2 (en) * | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
| CN111356700A (zh) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| US11673954B2 (en) | 2017-11-17 | 2023-06-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-L1 |
| KR20260039804A (ko) * | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| KR102834864B1 (ko) | 2018-02-02 | 2025-07-16 | 온코씨4, 아이앤씨. | 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체 |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| WO2019222282A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2019222278A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Dual binding moiety |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| EP3833444A1 (en) | 2018-08-09 | 2021-06-16 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| US20230132385A9 (en) | 2018-09-20 | 2023-04-27 | Tikcro Technologies Ltd. | Antibodies specific to ctla-4 and uses thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| MX2021006930A (es) * | 2018-12-11 | 2021-11-17 | Q32 Bio Inc | Construcciones de proteínas de fusión para enfermedades asociadas al complemento. |
| EP3911371A4 (en) * | 2019-01-18 | 2023-04-26 | University of Southern California | METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY |
| JP2022524337A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質 |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN113811546B (zh) * | 2019-05-07 | 2025-03-11 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| US20230220105A1 (en) | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| WO2020264200A1 (en) | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| AU2021326469C1 (en) | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| WO2022060878A1 (en) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
| CA3196055A1 (en) | 2020-09-28 | 2022-03-31 | Navrogen, Inc. | Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer |
| US20240043565A1 (en) | 2020-10-15 | 2024-02-08 | Janux Therapeutics, Inc. | Antibodies targeting psma and cd3 and uses thereof |
| US20240228656A1 (en) * | 2020-11-06 | 2024-07-11 | Harpoon Therapeutics, Inc. | Epcam targeting trispecific protein for treatment of cancer |
| WO2022125566A1 (en) | 2020-12-08 | 2022-06-16 | Janux Therapeutics, Inc. | Half-life extending compositions and methods |
| CN116981682A (zh) | 2020-12-08 | 2023-10-31 | 佳努克斯治疗公司 | 用于抗-cd3结合结构域的肽组合物和方法 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| KR20250024874A (ko) | 2022-04-04 | 2025-02-19 | 재눅스 테라퓨틱스 인크. | Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법 |
| US20240059790A1 (en) | 2022-04-04 | 2024-02-22 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
-
2021
- 2021-12-07 EP EP21904270.2A patent/EP4259193A4/en active Pending
- 2021-12-07 US US17/544,539 patent/US11555078B2/en active Active
- 2021-12-07 JP JP2023534888A patent/JP7850721B2/ja active Active
- 2021-12-07 AU AU2021396172A patent/AU2021396172A1/en active Pending
- 2021-12-07 CA CA3201588A patent/CA3201588A1/en active Pending
- 2021-12-07 TW TW114134630A patent/TW202617780A/zh unknown
- 2021-12-07 KR KR1020237022679A patent/KR20230135575A/ko not_active Ceased
- 2021-12-07 WO PCT/US2021/062249 patent/WO2022125576A1/en not_active Ceased
- 2021-12-07 TW TW110145581A patent/TWI900703B/zh active
- 2021-12-07 MX MX2023006817A patent/MX2023006817A/es unknown
-
2022
- 2022-11-16 US US18/055,932 patent/US12617865B2/en active Active
-
2025
- 2025-09-05 US US19/320,207 patent/US20260001963A1/en active Pending
-
2026
- 2026-01-09 JP JP2026002859A patent/JP2026084109A/ja active Pending
- 2026-03-18 US US19/570,589 patent/US20260217858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3201588A1 (en) | 2022-06-16 |
| EP4259193A1 (en) | 2023-10-18 |
| JP7850721B2 (ja) | 2026-04-23 |
| TW202617780A (zh) | 2026-05-01 |
| US20220177600A1 (en) | 2022-06-09 |
| JP2023552812A (ja) | 2023-12-19 |
| TW202237654A (zh) | 2022-10-01 |
| EP4259193A4 (en) | 2025-01-15 |
| TWI900703B (zh) | 2025-10-11 |
| JP2026084109A (ja) | 2026-05-20 |
| AU2021396172A1 (en) | 2023-07-06 |
| US20260001963A1 (en) | 2026-01-01 |
| US20230348618A1 (en) | 2023-11-02 |
| US12617865B2 (en) | 2026-05-05 |
| WO2022125576A1 (en) | 2022-06-16 |
| US11555078B2 (en) | 2023-01-17 |
| KR20230135575A (ko) | 2023-09-25 |
| US20260217858A1 (en) | 2026-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013382A (es) | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. | |
| TW202617780A (zh) | 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法 | |
| BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
| MX2024005009A (es) | Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. | |
| CO2021008568A2 (es) | Anticuerpos que se unen a cd3 | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| PE20171764A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 | |
| PE20170263A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
| CL2019000119A1 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123. | |
| CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
| ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| PE20180484A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
| MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
| CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
| AR094872A1 (es) | Anticuerpos anti-tnf-anti-il-17 biespecíficos | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
| MX2016006529A (es) | Anticuerpos dobles especificos. | |
| BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| CR20150393A (es) | Moleculas biespecíficas de union a antígeno activadoras de células t | |
| CR20220628A (es) | Anticuerpos que se unen a cd3 | |
| MX2024009272A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| CO2023010208A2 (es) | Proteínas de unión a psma y usos de estas |